Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

NASDAQ:CAMP - Nasdaq - US13463J1016 - Common Stock - Currency: USD

1.95  +0.05 (+2.63%)

Fundamental Rating

1

Overall CAMP gets a fundamental rating of 1 out of 10. We evaluated CAMP against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of CAMP have multiple concerns. CAMP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CAMP had negative earnings in the past year.
CAMP had a positive operating cash flow in the past year.
In the past 5 years CAMP reported 4 times negative net income.
In multiple years CAMP reported negative operating cash flow during the last 5 years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

CAMP's Return On Assets of -36.04% is fine compared to the rest of the industry. CAMP outperforms 60.56% of its industry peers.
Industry RankSector Rank
ROA -36.04%
ROE N/A
ROIC N/A
ROA(3y)-9.56%
ROA(5y)-8.32%
ROE(3y)-107.81%
ROE(5y)-74.4%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

With a decent Gross Margin value of 35.78%, CAMP is doing good in the industry, outperforming 74.12% of the companies in the same industry.
CAMP's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CAMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.78%
GM growth 5Y-2.17%
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

1

2. Health

2.1 Basic Checks

CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAMP has been increased compared to 1 year ago.
Compared to 5 years ago, CAMP has more shares outstanding
Compared to 1 year ago, CAMP has a worse debt to assets ratio.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

CAMP has an Altman-Z score of -0.16. This is a bad value and indicates that CAMP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.16, CAMP is in the better half of the industry, outperforming 63.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC4.08%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.69 indicates that CAMP should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.69, CAMP is doing worse than 79.75% of the companies in the same industry.
A Quick Ratio of 1.35 indicates that CAMP should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.35, CAMP is not doing good in the industry: 83.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.35
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CAMP have decreased strongly by -2244.44% in the last year.
Measured over the past 5 years, CAMP shows a small growth in Earnings Per Share. The EPS has been growing by 1.49% on average per year.
Looking at the last year, CAMP shows a decrease in Revenue. The Revenue has decreased by -0.30% in the last year.
Measured over the past years, CAMP shows a decrease in Revenue. The Revenue has been decreasing by -4.22% on average per year.
EPS 1Y (TTM)-2244.44%
EPS 3Y42.01%
EPS 5Y1.49%
EPS Q2Q%-305.07%
Revenue 1Y (TTM)-0.3%
Revenue growth 3Y-2.86%
Revenue growth 5Y-4.22%
Sales Q2Q%-99.17%

3.2 Future

The Earnings Per Share is expected to decrease by -43.72% on average over the next years. This is quite bad
Based on estimates for the next years, CAMP will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y-591.99%
EPS Next 2Y-109.86%
EPS Next 3Y-60.72%
EPS Next 5Y-43.72%
Revenue Next Year-99.95%
Revenue Next 2Y-97.24%
Revenue Next 3Y-93.03%
Revenue Next 5Y-18.92%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CAMP is valued cheaply inside the industry as 94.54% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.58
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

CAMP's earnings are expected to decrease with -60.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-109.86%
EPS Next 3Y-60.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (4/22/2025, 8:00:01 PM)

1.95

+0.05 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners50.65%
Inst Owner Change-0.34%
Ins Owners3.6%
Ins Owner Change0%
Market Cap39.31M
Analysts86
Price Target19.38 (893.85%)
Short Float %2.79%
Short Ratio6.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1121.97%
Min EPS beat(2)-2111.25%
Max EPS beat(2)-132.68%
EPS beat(4)1
Avg EPS beat(4)-514.08%
Min EPS beat(4)-2111.25%
Max EPS beat(4)263.11%
EPS beat(8)3
Avg EPS beat(8)-280.97%
EPS beat(12)6
Avg EPS beat(12)-187.52%
EPS beat(16)9
Avg EPS beat(16)-239.52%
Revenue beat(2)0
Avg Revenue beat(2)-57%
Min Revenue beat(2)-100%
Max Revenue beat(2)-14%
Revenue beat(4)0
Avg Revenue beat(4)-31.07%
Min Revenue beat(4)-100%
Max Revenue beat(4)-2.14%
Revenue beat(8)2
Avg Revenue beat(8)-16.14%
Revenue beat(12)2
Avg Revenue beat(12)-15.26%
Revenue beat(16)2
Avg Revenue beat(16)-15.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)59.75%
EPS NQ rev (3m)59.75%
EPS NY rev (1m)-15.4%
EPS NY rev (3m)-15.4%
Revenue NQ rev (1m)-99.72%
Revenue NQ rev (3m)-99.72%
Revenue NY rev (1m)-99.94%
Revenue NY rev (3m)-99.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF 8.02
P/B N/A
P/tB N/A
EV/EBITDA 28.58
EPS(TTM)-27.02
EYN/A
EPS(NY)-3.03
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.24
OCFY12.47%
SpS13.13
BVpS-3.68
TBVpS-5.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.78%
FCFM N/A
ROA(3y)-9.56%
ROA(5y)-8.32%
ROE(3y)-107.81%
ROE(5y)-74.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.78%
GM growth 5Y-2.17%
F-Score4
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 28.56
Cap/Depr 36.69%
Cap/Sales 3.02%
Interest Coverage N/A
Cash Conversion 61.37%
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.35
Altman-Z -0.16
F-Score4
WACC4.08%
ROIC/WACCN/A
Cap/Depr(3y)53.65%
Cap/Depr(5y)58.06%
Cap/Sales(3y)3.98%
Cap/Sales(5y)4.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2244.44%
EPS 3Y42.01%
EPS 5Y1.49%
EPS Q2Q%-305.07%
EPS Next Y-591.99%
EPS Next 2Y-109.86%
EPS Next 3Y-60.72%
EPS Next 5Y-43.72%
Revenue 1Y (TTM)-0.3%
Revenue growth 3Y-2.86%
Revenue growth 5Y-4.22%
Sales Q2Q%-99.17%
Revenue Next Year-99.95%
Revenue Next 2Y-97.24%
Revenue Next 3Y-93.03%
Revenue Next 5Y-18.92%
EBIT growth 1Y39.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5658.58%
EBIT Next 3Y-343.93%
EBIT Next 5Y-223.58%
FCF growth 1Y-0.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.12%
OCF growth 3YN/A
OCF growth 5YN/A